Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of “Moderate Buy” by Analysts

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) has received an average rating of “Moderate Buy” from the seven analysts that are presently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $66.6667.

TARS has been the subject of several analyst reports. Oppenheimer initiated coverage on shares of Tarsus Pharmaceuticals in a research report on Monday, June 2nd. They set an “outperform” rating and a $75.00 price target for the company. Zacks Research upgraded shares of Tarsus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, September 5th.

Tarsus Pharmaceuticals Price Performance

Shares of TARS opened at $55.26 on Thursday. The company has a market capitalization of $2.33 billion, a P/E ratio of -23.72 and a beta of 0.81. The company has a quick ratio of 5.21, a current ratio of 5.26 and a debt-to-equity ratio of 0.22. The firm has a 50 day moving average of $50.68 and a 200 day moving average of $47.04. Tarsus Pharmaceuticals has a twelve month low of $31.36 and a twelve month high of $59.76.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.15). The firm had revenue of $102.66 million for the quarter, compared to the consensus estimate of $95.81 million. Tarsus Pharmaceuticals had a negative net margin of 31.13% and a negative return on equity of 32.36%. As a group, equities research analysts anticipate that Tarsus Pharmaceuticals will post -3.17 earnings per share for the current fiscal year.

Insider Activity at Tarsus Pharmaceuticals

In related news, CEO Bobak R. Azamian sold 6,000 shares of the firm’s stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $50.00, for a total value of $300,000.00. Following the sale, the chief executive officer owned 818,106 shares in the company, valued at approximately $40,905,300. This trade represents a 0.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director William J. Phd Link sold 27,116 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $57.00, for a total transaction of $1,545,612.00. Following the completion of the sale, the director owned 143,332 shares in the company, valued at $8,169,924. This represents a 15.91% decrease in their position. The disclosure for this sale can be found here. Company insiders own 8.97% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Osaic Holdings Inc. boosted its stake in shares of Tarsus Pharmaceuticals by 779.1% during the 2nd quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock worth $113,000 after acquiring an additional 2,462 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Tarsus Pharmaceuticals by 9.6% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 8,438 shares of the company’s stock worth $342,000 after acquiring an additional 740 shares during the last quarter. Squarepoint Ops LLC boosted its stake in shares of Tarsus Pharmaceuticals by 78.0% during the 2nd quarter. Squarepoint Ops LLC now owns 102,642 shares of the company’s stock worth $4,158,000 after acquiring an additional 44,986 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Tarsus Pharmaceuticals by 220.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,045 shares of the company’s stock worth $164,000 after acquiring an additional 2,782 shares during the last quarter. Finally, Man Group plc purchased a new position in shares of Tarsus Pharmaceuticals during the 2nd quarter worth $1,098,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.